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Potassium channelThe HERG (human ether-a-go-go related gene) potassium channel aids in the repolarization of the car-
diomyocyte membrane at the end of each action potential. We have previously shown that sustained protein
kinase A or C (PKA and PKC) activity speciﬁcally enhances channel synthesis over the course of hours to days
in heterologous expression and cardiac myocytes. The kinase-mediated augmentation of the channel is post-
transcriptional and occurs near or at the endoplasmic reticulum. Here we report our further investigations
into the mechanisms of kinase-mediated augmentation of HERG channel protein. We show that HERG chan-
nel phosphorylation alone is not sufﬁcient for the PKA-dependent increase to occur. In vitro translation stud-
ies indicate that an additional factor is required for the process. Pharmacologic inhibitors suggest that the
channel augmentation is not due to kinase-mediated alteration in proteasome or lysosome activity. PKA ac-
tivation had no effect on stability of HERG mRNA and polyribosomal proﬁling showed that kinase activity did
not elevate translation from low to high rates. Transcriptional inhibition results suggest that the additional
cellular factor is a PKA-regulated protein. Together, these ﬁndings suggest that PKA-mediated augmentation
of HERG abundance is more complex than previously appreciated involving enhancement of already active
translation rates, phosphorylation of the channel protein and at least one other cyclic-AMP/PKA-responsive
protein. Further exploration of molecular components of this regulatory pathway will be necessary to deter-
mine exact mechanism and the biomedical impact of this process in vivo.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The HERG (human ether-a-go-go related gene [1]) gene encodes
the pore-forming α-subunit of the rapidly-activating delayed rectiﬁer
potassium channel IKr [2]. The HERG potassium channel function is
essential for maintaining normal heart rate and rhythm in humans.
HERG channels are homo-tetrameric and carry the ventricular repo-
larization current IKr during phase three of the cardiac ventricular ac-
tion potential. Mutations in the HERG gene are responsible for
approximately 40% of all cases of the hereditary Long QT Syndrome
(LQTS) [3]. LQTS may be a hereditary or an acquired cardiac disorder
that predisposes patients to life threatening arrhythmias that can lead
to syncope or sudden death. LQTS patients exhibit a prolonged inter-
val between the beginning of the Q wave and the end of the T wavene; HEK, human embryonic kid-
horbol 12-myristate 13-acetate;
bromocinnamylamino)ethyl]-5-
Forchheimer G35, Bronx, NY
989.
. McDonald).
rights reserved.on body surface electrocardiograms. Hereditary HERG channel dys-
function occurs through deleterious mutations, whereas acquired
LQTS can occur due to drug blockade of the channel pore or dys-
regulation of wild-type channels.
For patients with HERG mutations, cardiac events are often trig-
gered by strong emotional or startling stimulus such as an alarm
clock ringing and to a lesser extent with physical exertion [4]. Such
triggers presumably increase the catecholamine concentration caus-
ing an acute rise in the adrenergic stimulation. In LQTS, electrical
rhythm disturbances often degenerate into a dangerous form of poly-
morphic ventricular tachycardia called Torsades des Pointes [5]. An
LQTS mutant HERG as in hereditary LQTS or a pharmacologically
blocked HERG channel as in acquired LQTS would not respond appro-
priately in the setting of increased adrenergic stimulus and thus
might lead to arrhythmia.
Previous work from several groups has shown that the K+ current
characteristics are acutely regulated by both α- and β-adrenergic
stimulation [6–8]. Earlier studies showed that the acute effects of β-
adrenergic signaling on HERG channel regulation are mediated di-
rectly via protein kinase A (PKA) phosphorylation of the channel
and as well through direct binding of cAMP to the cyclic nucleotide
binding domains on the channel [6]. A second level of β-AR/PKA
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teins such as 14-3-3, which binds to HERG when the channel is phos-
phorylated and affects channel gating and duration of the response
[9,10]. Additionally, our group showed that an A-kinase anchoring
protein (AKAP) is likely involved in targeting PKA to HERG in a mac-
romolecular complex, which facilitates current modulation [11].
While the acute regulation has been well studied, the long-term
adrenergic regulation of HERG is less clear. Our group has demon-
strated that chronic β- and α-adrenergic stimulation distinctly en-
hances channel abundance over the time period of hours to days
[12,13]. The increase in HERG abundance did not appear to be at the
level of transcription but did show accelerated channel synthesis.
For the PKA‐mediated increase in HERG abundance, PKA activity
must be localized to the surface of the ER [14]. We failed to observe
similar kinase-mediated effects on other cardiac channels (KCNQ1,
Kv1.5, and Kir2.1) [12,13]. Thus, we postulated that synthesis of the
HERG channel is unusual in its responsiveness to the activity of ki-
nases (PKA and PKC). Understanding which molecular components
are involved and the signaling steps in this regulatory pathway is like-
ly to reveal potential pharmacological targets for future therapies in
acquired and hereditary forms of LQTS. In the present study, we
sought to identify mechanisms responsible for the speciﬁc protein-
kinase mediated increase in HERG protein abundance. We have
determined: 1) that channel phosphorylation is necessary but not
sufﬁcient for the full increase to occur; 2) that a cellular co-factor is
required for the kinase-induced increase in HERG channel abundance;
3) that changes in degradation pathways via the proteasome or lyso-
some do not account for the increase in HERG protein abundance;
4) that cAMP does not alter the stability of HERG mRNA signiﬁcantly;
5) that there is not a measurable change in the association of HERG
mRNA from low to highly translating ribosomes; and lastly 6) that the
cellular co-factor is likely to be a cAMP/PKA-responsive protein.
2. Materials and methods
2.1. Reagents
Unless otherwise noted, all chemicals were purchased from
Sigma-Aldrich (St. Louis, MO) and Fisher Scientiﬁc (Waltham, MA).
Small molecule activators and inhibitors were used at the following
ﬁnal concentrations: 50 μM 8-(4-chlorophenylthio)-adenosine-3′,5′‐
cyclic monophosphate (CPT-cAMP), 10 μM H-89, 10 nM phorbol 12-
myristate 13-acetate (PMA), 10 μM bisindolylmaleimide-1 (bis-1),
2 μM lactacystin, 750 μMMG132, 10 mMNH4Cl, 50 nM concanamycin
A, and 5 μg/ml actinomycin-D. Dimethylsulfoxide (DMSO) was used
as the vehicle at a concentration of less than 0.1% in media. Antibodies
against HERG were rabbit polyclonal H175, mouse monoclonal 9e10,
and rabbit polyclonal A14 anti-myc antibodies (Santa Cruz Biotech,
Santa Cruz, CA). Other antibodies used were pan-14-3-3 K-19
(Santa Cruz), PKA catalytic subunit‐α (BD Biosciences, Franklin
Lakes, NJ), PKA regulatory subunit RIIα (BD Biosciences), PKC isoform
antibodies (BD Biosciences) and ubiquitin (Santa Cruz). Loading con-
trol antibodies used were against Na+/K+-ATPase (Thermo Fisher,
Waltham, MA) and tubulin (Sigma).
2.2. Cell culture, transfection and plasmids
For all experiments, HEK 293 (American Type Cell Culture, Manas-
sas, VA) cells were maintained in RPMI1640 (Mediatech, Manassas,
VA) supplemented with 10% fetal bovine serum (Hyclone/Thermo
Fisher) and 10,000 IU of penicillin/streptomycin (Mediatech). Cells
were kept at 37 °C with humidiﬁed air and 5% CO2. For some experi-
ments culture dishes were coated with poly‐L-lysine in 0.5% gelatin to
help adherence.
Wild-type HERG was expressed with a C-terminal myc-tag in the
pCI-neo mammalian expression vector as previously described [15].The Δ1234-HERG is a mutated version in which the four PKA phos-
phate acceptor residues have been changed to alanine and preventing
phosphorylation of the channel by PKA (S283A, S890A, T895A, and
S1137A). Construction of this plasmid has been described earlier
[6,13]. The HERG-SD mutant contains four point mutations: S283D,
S890D, T895D, and S1137D. This construct was created by sequential
site directed mutagenesis of myc-tagged HERG in vector pCI-neo
using the Quik-Change kit (Stratagene, Santa Clara, CA) (A more
detailed description of the creation and characterization of the
HERG-SD plasmid is given in the Supplemental Materials section).
Mutations were conﬁrmed by automated commercial sequencing
(Genewiz Inc., South Plainﬁeld, NJ). A second HERG construct was
used where the HERG coding sequence was inserted as a restriction
fragment (BamHI and HinDIII) into the multicloning site of pCMVtag3a
vector (Stratagene) with an N-terminal myc-tag. This vector was used
for in vitro translation experiments due to convenient restriction
sites and RNA T3 polymerase site 5′ to the start codon. Moreover the
N-terminal myc-tag allowed for immune-identiﬁcation of all partially
translated HERG products. 14-3-3ε was cloned into pcDNA3 vector
(Invitrogen Life Sciences, Carlsbad, CA) at EcoRI and XhoI sites [9].
R56,60A 14-3-3η in pcDNA3.1 vector was a generous gift from
Dr. Andrey Shaw (Washington University, St. Louis, MO). Difopein, a
dimer of R18, a competitive binding inhibitor of all 14-3-3 isoforms
[16], fused with c-Myc tag, was inserted into a pEGFP-C1 vector
(Clontech, Mountain View, CA).
Various constructs were expressed in HEK-HERG stable cells by
transient transfection using LipofectAMINE 2000 (Invitrogen) in
Opti-MEM medium (Gibco/Invitrogen). A total of 5 μg of DNA
(pCDNA3-14-3-3ε, pcDNA3.1-R56,60A 14-3-3η (Δη), or pEGFP-Myc-
Difopein) combined with 12 μl of LipofectAMINE 2000 diluted in
8 ml of Opti-MEM was used to transiently transfect one 100-mm
dish with 80–90% conﬂuence. Transfection medium was replaced by
RPMI 1640 medium 6 h later. Membrane permeable cAMP analog
CPT-cAMP (Sigma) was added to culture dish 10 h after transfection.
Cells were analyzed 48 h after transfection. A green ﬂuorescent pro-
tein (GFP) reporter plasmid (Clontech) was used to monitor transfec-
tion efﬁciency (at a molar ratio of 1:4 compared to that of the study
plasmid). Stably transfected HEK-HERG and HEK-HERG-SD cells
were created via limiting dilution cloning as previously described
[11].2.3. Western blots and immunoprecipitation
Forty-eight hours after transfection with the desired expression
plasmids, HEK 293 cells were lysed with ice-cold NDET buffer (1%
NP-40, 0.4% Deoxycholic acid, 5 mM EDTA, 25 mM Tris,150 mM
NaCl, pH 7.5) with complete protease inhibitor cocktail (Roche, Indi-
anapolis, IN) for 15 min. Cell lysates were centrifuged at 13,000 rpm
at 4 °C for 10 min to remove nuclei and insoluble debris, and the su-
pernatants were mixed with SDS-PAGE loading buffer. Proteins
were separated by 7.5% SDS-PAGE and transferred to nitrocellulose
membranes (Bio-Rad, Hercules, CA) by semi-dry blotting unit (Fisher
Biotech). The nitrocellulose membranes were blocked with Tris-
buffered saline containing 0.5% Tween-20 (TBS-T) and 5% non-fat
dry milk for 30 min at room temperature, and then incubated with
primary antibody overnight at 4 °C. The membrane was washed
with TBS-T and then incubated in the corresponding infrared-
ﬂuorescence IRDye® 800 conjugated donkey anti-mouse and
IRDye® 700DX conjugated donkey anti-rabbit secondary antibodies
(1:10,000, Rockland Immunochemicals Inc., Gilbertsville, PA) for
30 min at room temperature in the dark followed by washing with
TBS-T. The membranes were then scanned to visualize the signal at
680 nm or 780 nm by the Odyssey detection system (Li-Cor Biosci-
ences, Lincoln, NE) and densitometry of the protein bands was per-
formed using Li-Cor software.
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post-nuclear lysate was taken after a spin at 13,000 rpm at 4 °C. A
portion of the lysate was saved as input and the rest of the lysate
was ﬁrst pre-cleared for 30 min with non-speciﬁc IgG and then
30 min of protein A/G beads (Santa Cruz) at 4 °C. The pre-cleared ly-
sate was then immunoprecipitated for HERG using the myc-antibody
overnight at 4 °C. Fresh protein A/G beads were added and incubated
for 3 h at 4 °C. The lysate was then spun, the supernatant was re-
moved and beads were washed in NDET three times. A small volume
of 4× SDS-PAGE loading buffer (Laemmli's buffer) was added to the
beads and eluted for 30 min at room temperature. The samples
were then separated on 4–15% gradient gels, transferred and blotted
as described above.
2.4. In vitro translation
In vitro translation (IVT) experiments were done using the
Promega micrococcal nuclease treated rabbit reticulocyte system
and the protocol was adapted from Lu and Deutsch [17]. A plasmid
containing the HERG coding sequence in pCMVtag3a was linearized
using a restriction digest with MluI (New England Biolabs). Comple-
mentary RNA containing the 5′ cap was transcribed in vitro from lin-
earized plasmid DNA using the T3 Message Machine kit and puriﬁed
on the MEGAClear column (Ambion/Life Sciences, Carlsbad, CA). The
plasmid constructs (in pCMVtag3a) contained the HERG coding re-
gion but did not contain 5′ or 3′ untranslated regions. Proteins were
synthesized in the presence of 35S-methionine (EasyTag, Perkin
Elmer, Waltham, MA) (1 μL per 25‐μL reaction at a concentration of
10 μCi/μL) for 0 to 60 min at 30 °C according to manufacturer's in-
structions. The small peptide inhibitor PKI 6–22 amide was added as
indicated to a ﬁnal concentration of 10 μM. For each sample 200 ng
of cRNA was used for each 25-μL reaction. The reaction contained all
essential reagents with canine pancreatic microsomal membranes
and RNAsin RNAse inhibitor (Promega). Reactions were quenched
on ice, in 4× volume of buffer composed of 20 mM HEPES, 4 mM
MgCl2, 100 mM NaCl, and 1 mM DTT, pH 7.4–7.5. The quenched
translation reactions were loaded onto a sucrose cushion of equal vol-
ume (containing 0.5 M sucrose, 100 mM KCl, 5 mM MgCl2, 50 mM
HEPES, 1 mM DTT, pH 7.5) and subjected to ultra-centrifugation
using a TLA100.1 Beckman rotor at 77,000 rpm (200,000×g) for
30 min at 4 °C. The supernatant was removed and the pellet was re‐
suspended in 10 μl of quench buffer and 10 μL SDS-PAGE sample buffer.
Samples were loaded on to 4–15% gradient Tris-glycine gels and elec-
trophoresed at constant voltage (Bio-Rad). Gels were then transferred
using the semi-dry electro-blotting system onto nitrocellulose mem-
branes. Membranes were then soaked in a solution of 0.5 M sodium sa-
licylate, 5% methanol and 10% glycerol for 10 min and then exposed to
ﬁlm at−80 °C for autoradiography.
2.4.1. IVT analysis
Autoradiography ﬁlms were scanned and converted into digital
ﬁles for densitometry analysis using ImageJ (National Institutes of
Health) [18,19]. Line scan analysis was done by taking a vertical line
region of interest (ROI) for each lane. The values were then normal-
ized from 0 to 1 and the highest peak, representing full-length prod-
uct, was aligned.
For an additional quantitative measure 35S-methionine incorpora-
tion membranes were washed in Tris-buffered saline with Tween 20
(TBS-T) and then Ponceau S stained to visualize total protein and
lane boundaries. Next, pieces were cut from each lane for liquid scin-
tillation counting and quantitation. For HERG, a piece was cut be-
tween the molecular weight markers for 100–150 kDa, representing
full‐length product, and the rest of the lane representing the remain-
der was counted separately. Membrane pieces were dissolved in
Filtron-X liquid scintillation cocktail (National Diagnostics, Atlanta,
GA). The ratio of 35S-methionine counts was calculated by takingthe counts for full-length product divided by the counts of the re-
mainder of the lane.
To determine the activity of PKA in the IVT systemwe used in vitro
phosphorylation of the IVT lysate as previously published but with
modiﬁcations [6]. In this case additional puriﬁed PKA catalytic sub-
unit was either included or omitted but the IVT reaction lysate was
complemented by 10 μM [γ-32P] ATP for 1 h at 30 °C. The reaction
was terminated with ice-cold NDET buffer. The reaction mix was
then subject to the centrifugation on sucrose cushion, as above, and
separated on SDS-PAGE followed by autoradiography. Endogenous ki-
nase was stimulated by cAMP and inhibited by staurosporine and the
peptide PKI addition.
2.5. Polysomal proﬁling
Linear 10–50% (w/v) sucrose gradients were prepared by consec-
utively freezing each layer until all ﬁve layers were added. Sucrose so-
lutions of 10%, 20%, 30%, 40%, and 50% were made in the following
buffer: 10 mM Tris pH 7.4, 100 mM NaCl, 2.5 mM MgCl2 and RNAsin.
For each Sw 41Ti tube, 2 ml of 50% sucrose was added to the bottom,
frozen, the next 2 ml layer of 40% sucrose added, frozen, etc., until all
ﬁve layers were added. Frozen gradients were thawed overnight at
4 °C and ready to use the next day.
For polysomal proﬁling experiments, two 15 cm plates of stably
transfected HEK-HERG cells (approximately 70% conﬂuent) were
used per gradient. Prior to lysis, cells were treated with 100 μg/ml cy-
cloheximide for 10 min at 37 °C. Dishes were placed on ice and cells
were lysed on ice in a buffer composed of 100 mM NaCl, 2.5 mM
MgCl2, 25 mM, Tris–HCl pH 7.5, 1% NP-40, 0.4% sodium deoxycholate,
1 mM DTT, 100 μg/ml cycloheximide, and RNAsin. The lysate was
spun at 13,000 rpm on a table top centrifuge at 4 °C for 10 min. A por-
tion of the cleared lysate was saved for the total RNA measurement.
The rest of the lysate (about 1–1.5 ml) was layered onto the top of
the sucrose gradient. Gradients were spun at 38,000 rpm for 2 h at
4 °C using a Sw 41Ti rotor and Beckman Optima LE ultracentrifuge.
RNA was detected by measuring the absorbance at 254 nm using
an ISCO UA-6 continuous UV reader. For each gradient, 1-ml fractions
were collected into tubes containing 200 μl of 1% SDS. RNA was then
extracted from the fractions by sodium acetate and ethanol precipita-
tion with incubation at −80 °C overnight. The samples were cen-
trifuged at 13,000 rpm for 10 min at 4 °C using a table top
centrifuge. The RNA pellets were re-suspended and puriﬁed using
the RNEasy Mini Kit (Qiagen, Valencia, CA).
2.6. Quantitative real-time PCR
First-strand synthesis was done on the pooled RNA gradient-
fractions using the SuperScript VILO cDNA synthesis kit (Invitrogen).
Groups of gradient-fractions were combined using equal volumes of
RNA such that the total starting concentration for the ﬁrst strand syn-
thesis reactions was 2500 ng. The primers were a mix of oligo-dT and
random hexamers. The reaction proceeded as follows using the Veriti
thermo-cycler (Applied Biosystems, Carlsbad, CA): 10 min at 25 °C,
50 min at 50 °C, 5 min at 85 °C and the ﬁnal step included addition
of E. coli RNAse (Ambion) for 25 min at 37 °C.
After ﬁrst strand synthesis, qRT-PCR was done using Power SYBR
green Master Mix and the Step One System (Applied Biosystems).
Primers for HERG, GAPDH and β-actin were commercially synthe-
sized (IDT DNA, Coralville IA). Reactions were prepared in triplicate.
Cycling conditions were as follows: a holding stage 2 min at 50 °C
and 10 min at 95 °C, 40 cycles of 15 s at 95 °C, 1 min at 60 °C, 30 s at
72 °C, and a ﬁnal melt curve stage of 15 s at 95 °C, 1 min at 60 °C,
and 15 s at 95 °C.
Data were collected using the Step One Software to determine
threshold-cycle (Ct) for relative quantiﬁcation. Data analysis for
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for each fraction.
For experiments on total RNA samples (as in Fig. 4A), total HEK-
HERG cellular RNA was obtained by lysis in NDET with RNAsin
followed by a spin at 13,000 rpm to remove nuclei and debris. The
cleared lysate was then puriﬁed using the RNEasy Mini kit as directed
by manufacturer's instructions. The total RNA samples were quanti-
ﬁed and then subjected to ﬁrst strand synthesis and qRT-PCR as
above. Analysis was done using the delta-delta Ct method and fold
change in HERG mRNA was calculated using GAPDH as the control
for normalization.
Primer sequences: HERG forward: 5′ TCAACCTGCGAGATACCAACATG
3′ and reverse: 5′ CTGGCTGCTCCGTGTCCTT 3′. GAPDH forward: 5′
TCAACGACCACTTTGTCAAGCTCA 3′ and reverse: 5′ AGTAAGACCCCTG-
GACCACCAGC 3′. Actin forward: 5′ CTCTTCCAGCCTT-CCTTCCT 3′ and
reverse: 5′ CTGTACGCCAACACAGTGCT 3′.
2.7. Statistics
All data are expressed as the mean±SEM. The two-tailed Stud-
ent's T-test was used for pair-wise comparisons and a p value of less
than 0.05 was considered signiﬁcant. For experiments comparing
more than two means against the control condition, one-way
ANOVA with Dunnett's test was used with a p value less than 0.05
considered signiﬁcant.
3. Results
3.1. Phosphomimetic HERG mutant protein abundance also increases
with kinase stimulation
We have previously studied the effects of kinase stimulation by
cAMP on HERG protein abundance and found that phosphorylation
of HERG is likely involved [12,13]. To further characterize the partic-
ipation of channel phosphorylation in cAMP/PKA enhancement of
HERG abundance we compared wild‐type HERG (WT HERG);
phospho-null mutant HERG (S283A, S890A, T895A, and S1137A
known as Δ1234-HERG, which cannot be phosphorylated by PKA);
and a phosphomimetic mutant HERG (HERG-SD) (Fig. 1). In previous
studies we showed that the Δ1234-HERG responded to PKA stimula-
tion with minimal enhancement of channel protein [13]. We also cre-
ated the PKA phosphomimetic mutant S283D, S890D, T895D, and
S1137D (HERG-SD) where aspartic acid side chains resemble the
chemical structure of a phosphorylated serine. HERG-SD appeared
as a doublet on Western blot similar to wild‐type HERG (Fig. 1A,C).
In transient transfections using the same amount of initial plasmid
DNA, the normalized expression level of HERG-SD on Western blot
was 1.46±0.7 compared to HERG-WT at 1.0 however; this difference
was not statistically signiﬁcant (p value=0.5 and n=4). The mor-
phology of HERG-SD currents and voltage dependence of activation
were similar to wild‐type (Supplemental Fig. 1). HEK cells stably ex-
pressing HERG-SD were created and then subjected to 24-hour kinase
activation and/or inhibition. In side-by-side comparison wild‐type
HERG showed a three-fold increase in protein abundance upon CPT-
cAMP treatment and a six-fold increase upon PMA treatment
(Fig. 1A–B). For HERG-SD cAMP treatment resulted in a two-fold in-
crease and PMA treatment resulted in a four-fold increase (Fig. 1C–D).
The inhibitor treatments mildly suppressed the abundance of wild
type and HERG-SD. When CPT-cAMP stimulation of cells expressing
Δ1234-HERG and WT HERG were compared, side-by-side, Δ1234-
HERG showed a smaller degree of induction of channel protein (Fold
change=1.64±0.125) compared to the increase in WT HERG (Fold
change=3.97±0.355) (Fig. 1E,F). This induction however was smaller
than that seen for the HERG-SD mutant. Taken together, these ﬁndings
suggest that channel phosphorylation is necessary but not sufﬁcient to
produce the entire increase in HERG abundance in response to kinasestimulation. One caveat however, is that aspartic acid substitution
may not entirely mimic all properties of a phosphorylated serine (or
threonine) and therefore the HERG-SD mutant may not behave exactly
like a phosphorylated channel.
3.2. In vitro translation (IVT) method reveals that a cellular co-factor is
necessary for changes in HERG protein abundance
In our initial work we found that the cAMP/PKA-dependent in-
crease in HERG was detectable as early as 60 min and metabolic la-
beling studies indicated that the increase was due to enhanced
synthesis within 10–20 min [13]. In order to study the speciﬁc re-
quirements for this enhanced synthesis regulation we sought to re-
constitute the activity with the rabbit reticulocyte lysate (RRL).
Such a reductionist method would allow us to precisely control
those factors that might contribute to the regulation. The goal
was to determine if activity of PKA alone could reproduce the in-
crease in HERG protein abundance in the RRL in vitro system.
Upon initial assessment of the RRL components, we found that
there was an easily detectable amount of PKA catalytic subunit al-
ready present in the system whereas PKC isoforms could not be
detected (Fig. 2A). Using puriﬁed complementary RNA of the full‐
length HERG coding sequence in the translation reaction, we
obtained a strong channel translation signal via incorporation of
35S-Methionine (Fig. 2B). The full‐length product is about 130 kDa
(indicated by arrow), which agrees with the expected size of non-
glycosylated HERG [20]. The radio-labeled full-length and interme-
diate products were further identiﬁed as HERG by immunoblot analysis
(Supplemental Fig. 2).We next assayed for PKA-dependence in synthe-
sis rates of HERG by perturbing PKA activity. When the PKA inhibitor,
PKI 6–22 amide was included in the reaction we expected that the
amount of HERG translation would decrease however, we found that
there was no change in the amount of full-length protein produced or
in the pattern of intermediate HERG products over the time course of
0 to 60 min (Fig. 2B). Quantiﬁcation of the ratio of ﬁnal product over
the total amount of intermediate products contained in the rest of the
lane (a measure of translation efﬁciency) showed no differences be-
tween the baseline and PKI treated condition at all time points assayed
(Fig. 2C). Analysis of the pattern of intermediate products by line scans
also showed no consistent differences in the amount or position of
smaller molecular weight bands (Fig. 2D). The line scan pattern of
peaks was very reproducible between experiments. The peaks indicate
accumulation of various intermediate length productswhere theremay
be slower or stalled translation, while the valleys would represent
regions of the HERG peptide that are elongated rapidly enough as to
prevent accumulation. Thus, the discrete peaks at ~40 and ~70 kDa sug-
gest areas of slowed translation elongation or stalled ribosomes. When
PKA activity was enhanced in the IVT system by additional puriﬁed PKA
catalytic subunit and ATP there was no signiﬁcant change in the rate
of HERG translation despite measurable kinase activity (Supplemental
Figs. 2 and 3). Furthermore, we observed an IVT pattern similar to
HERG with another cardiac K channel, KCNQ1—addition of exoge-
nous PKA catalytic subunit plus ATP failed to alter its translation rate
(Supplemental Fig. 4). Thus, minimal cell-free translational machinery
for HERG could not be regulated by PKA activity as occurs in intact
cells. This indicates that 1) PKA activity is not required for the synthesis
of HERG at baseline and 2) it also suggest that there may be a factor re-
quired for the increase in HERG synthesis that is present in HEK293 cells
but is not present in the rabbit reticulocyte lysate system.
3.3. Proteasomal inhibition does not mimic the kinase-induced increase
in HERG protein
Although our results were most consistent with cAMP/PKA en-
hancement of HERG abundance from accelerated synthesis we
sought to carefully examine possible contribution of channel
Fig. 1. Kinase stimulation and inhibition modulate protein abundance of HERG-WT and HERG-SD.Parts A and C are representative immunoblots from HEK-HERG wild type and HEK-
HERG-SD phosphomimetic mutant stably transfected cells after 24‐hour treatment with control (DMSO), CPT-cAMP, H89, PMA, and bisindolylmaleimide-1 (bis-1). HERG appears as
a doublet at 135 and 155 kDa and tubulin was used as the loading control. Parts B and D show quantiﬁcation and summary data for the experiment. In part B, cAMP and PMA treat-
ment causes a three- and six-fold increase in wild‐type HERG protein abundance when normalized to tubulin. H89 and Bis-1 show slight decreases in HERG abundance. Part D
shows that HERG-SD the phosphomimetic mutant increases in protein abundance upon both PKA and PKC activation. CPT-cAMP treatment results in a two-fold increase in
HERG-SD while PMA causes a four-fold increase. Drug treatment samples were compared to the control, n=5 and * p valueb0.05, ** p valueb0.01. Part E is an immunoblot showing
lysate from stably expressing HEK-HERG Δ1234 after treatment with control DMSO or CPT-cAMP. Lanes 1 and 2 show blots from cells expressing WT HERG and lanes 3 and 4 show
from cells expressing Δ1234HERG. Tubulin was used as the loading control. Part F shows quantiﬁcation of the fold change in WT HERG and Δ1234 HERG protein abundance nor-
malized to tubulin where the DMSO controls were normalized to 1 (n=2).
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the proteasome and lysosome pathways separately. Fig. 3 shows
proteasome inhibition studies using lactacystin and MG132 in HEK-
HERG cells stably expressing the channel. Lactacystin and MG132 are
both cell permeable and speciﬁc inhibitors of proteasome subunits.
Fig. 3A and B shows the effect of proteasome inhibition as compared
to cAMP treatment. The immunoblot shows 24‐hour treatment using
the drugs alone or in combination. Proteasome inhibition did not
signiﬁcantly change the level of total HERG above control values. Fur-
thermore, proteasome inhibition failed to signiﬁcantly alter the PKA-
dependent HERG augmentation. With proteasome inhibitor treatment
there is less of the 155 kDa form of HERG and this is a consistent ﬁnding
amongother groups [21,22]. In Fig. 3C andD the same assaywas repeat-
ed but used PMA treatment to stimulate PKC. As with cAMP/PKA stim-
ulation, the changes in HERG abundance due to proteasome inhibition
do not mimic the increased due to PKC activation, nor does proteasome
inhibition signiﬁcantly impact the kinase effect. As a positive control,
we assayed total ubiquitin level as an indication of effective inhibition
of the proteasome. Fig. 3E and F shows the proteasome inhibitors pro-
duced the expected increase in total ubiquitin, while kinase stimulation
(via PKA or PKC) does not increase total ubiquitin-conjugated proteins.Furthermore, lysosomal inhibition was carried out using NH4Cl and
concanamycin A which are two methods that interfere with acidiﬁca-
tion of the lysosome, thereby reducing the proteolytic activity. After
24 h of lysosomal inhibition no signiﬁcant changes in HERG protein
abundance was observed suggesting that kinase-mediated effects
were unlikely due to reduction lysosomal degradation of the channel
(Supplemental Fig. 4).
3.4. cAMP treatment does not alter HERG mRNA stability
Another possible mechanism for kinase augmentation of HERG
that we considered was whether the stability of HERG mRNA was en-
hanced upon PKA stimulation. To test this we evaluated the mRNA
abundance by quantitative RT-PCR after treatments with actinomycin-
D (an inhibitor of new RNA transcription) over a time course after com-
bination actinomycin-D and cAMP administration (Fig. 4A). In the
presence of actinomycin-D serial measurements of mRNA will reﬂect
its rate of degradation within the cell. HEK-HERG cells were treated
with DMSO vehicle (control), 5 μg/ml actinomycin-D alone, or 5 μg/ml
actinomycin-D together with 50 μM CPT-cAMP added simultaneously
and cells were incubated for 6, 12, or 24 h. The cells were then lysed
Fig. 2. In vitro translation reveals that a cellular co-factor is necessary for changes in
HERG protein abundance.Part A shows immunoblots of PKA and PKC isoforms. Top
blot shows PKA catalytic subunit is present in H= HEK293 lysate, HH= HEK-HERG ly-
sate, and RRL = rabbit reticulocyte IVT lysate. Bottom three blots show PKC isoforms α,
δ, and ε are present in HEK293 and HEK-HERG lysate but absent in rabbit reticulocyte
lysate. Part B shows an 35S autoradiograph of labeled in vitro translation products of
HERG at ﬁve time points from 10 to 60 min and under the control condition (left
half) or with addition of 10 μM PKI (right half). Arrow indicates full‐length HERG trans-
lation product at ~130 kDa. Part C shows quantiﬁcation and summary data of in vitro
translation experiments. The points graphed represent the ratio of 35S counts of the
full‐length product over that of the total lane at each time point. The points of the con-
trol experiment and the experiment with PKI addition are not statistically different,
n=3. Part D shows a line scan plot where normalized image densitometry of the 35S
autoradiograph is plotted against increasing molecular weight. This analysis was
done at 60 min of translation. Black line represents the control condition while red
line represents the PKI treated condition. All plots were normalized to the value of
the highest peak representing the full‐length HERG product and to zero for the
baseline.
Fig. 3. Proteasome inhibition does not mimic kinase stimulation.Parts A, C, and E show
immunoblots from HEK-HERG stable cells treated with proteasome inhibitors and ki-
nase stimulators. Part A shows a Western blot with the effect of proteasome inhibitor
treatments with lactacystin (Lact), MG132, and combination treatment (L+M) to
CPT-cAMP treatment (cAMP) and a combination of proteasome inhibitors plus CPT-
cAMP (L+M+C). HERG appears as a doublet and tubulin was used as a loading con-
trol. Part B shows quantiﬁcation and summary data for part A. Fold change in the
ratio of total HERG over tubulin is plotted per treatment condition. Control levels are
normalized to 1.0 as indicated by dotted line. The differences between control and
proteasome inhibition samples were not statistically signiﬁcant. The differences be-
tween control samples and cAMP treated samples were statistically signiﬁcant, n=5
*** p valueb0.001. Part C shows Western blots from HEK-HERG stable cells treated
with proteasome inhibitors and PMA. Part D shows quantiﬁcation and summary data
for part C. Fold change in the ratio of HERG over tubulin is plotted for each treatment
condition. The differences between control and proteasome inhibition samples were
not statistically signiﬁcant. The differences between control samples and PMA treated
samples were statistically signiﬁcant, n=5 ** p valueb0.01 and *** p valueb0.001.
Part E shows Western blots for total ubiquitin under control, proteasome inhibition, ki-
nase stimulation, and combination treatments. Ubiquitin appears as a smear and tubu-
lin was used as a loading control. Part F shows quantiﬁcation and summary data for
part E. Fold change in the ratio of ubiquitin over tubulin is plotted per treatment con-
dition. Control levels were normalized to 1.0 as indicated by dotted line. The difference
between control and kinase treated samples was not signiﬁcant. The differences be-
tween control and proteasome inhibition samples were statistically signiﬁcant,
n=10 ** p valueb0.01 and *** p valueb0.001.
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the RNEasy mini kit and analyzed through quantitative RT-PCR. We
found that for both control and cAMP-stimulated cells actinomycin-D
markedly reduced theHERGmRNA levels as expected. The combination
actinomycin-D plus CPT-cAMP did not change the degree of HERG
mRNA compared to actinomycin-D treatment alone at each of the
three time points. This indicates that cAMP/PKA stimulation did not sig-
niﬁcantly alter the stability of HERG mRNA over 24 h.
3.5. Polysomal proﬁling of HERG mRNA during kinase stimulation
Polysomal proﬁling is a method to determine relative distribution
of an mRNA into pools with varying degrees of ribosomal occupancy
that reﬂects translation activity. Changes in translation rates from
low to high can be directly assayed by quantifying speciﬁc mRNAs
among the polysomal proﬁle. A redistribution of HERG mRNA from
less-active polysome pools to more actively polysome pools during
kinase activation would signify a direct enhancement in translation
rate. We performed polysome proﬁle analysis in HEK-HERG cells
with quantitative real-time PCR (qRT-PCR) for baseline control and
CPT-cAMP treatment conditions. Fig. 4B–C shows polysome proﬁles
for untreated and 6-hour treatment with CPT-cAMP. We chose this
time point because previous studies indicated that changes in HERGprotein abundance acceleration after kinase stimulation were most
noticeable at 4–8 h [13]. Fig. 4B shows a polysome proﬁle where the
y-axis represents absorbance at 254 nm quantifying RNA concentra-
tion. The x-axis represents the direction of sedimentation where the
highest density components are towards the right. The peaks of the
proﬁle from left to right represent the lightest components such as
small soluble RNAs or mRNAs unassociated with ribosomes. The
next large peak indicates the monosome fraction which mainly con-
sists of mRNA occupied by a single ribosome. The monosome fraction
is considered to represent least actively translatedmessages. The next
group of peaks represents polysomes which are two or more ribo-
somes occupying an mRNA molecule which we separated into low
molecular weight and high molecular weight polysomes (fractions 3
and 4). mRNAs that associate with polysomes are considered more
Fig. 4. cAMP treatment does not alter HERG mRNA stability nor alter the association with polysomes.Part A shows quantiﬁcation of HERG mRNA levels (normalized to GAPDH
mRNA levels) by quantitative real-time PCR for an experiment testing the stability of HERG mRNA after treatment with actinomycin-D alone (act-D) or in combination with
CPT-cAMP (act-D+cAMP) over a time course. HERG mRNA levels were compared between the control condition (DMSO treated) and act-D or act-D+cAMP treatments at each
of the three time points 6, 12 and 24 h. Control sample fold change was normalized to 1.0, act-D treatment is shown in gray and act-D+cAMP treatment is shown in black. The
differences between act-D and act-D+cAMP treatments were not statistically signiﬁcant at any time point, n=3.Parts B and C show a separate experiment, they are polyribosomal
proﬁles for untreated and 6-hour CPT-cAMP treated conditions. The y-axis shows absorbance at 254 nm plotted against increasing gradient density where heaviest components will
sediment to the right. The underlined segments 1–4 show where fractions were collected for subsequent qRT-PCR. Parts D–F show summary data for results of qRT-PCR. The y-axis
values represent percent of total RNA that is comprised by (D) HERG, (E) GAPDH, and (F) Actin, respectively per fraction. Open bars show the untreated condition while shaded bars
show the cAMP treated condition. Differences between treated and untreated conditions were not signiﬁcant, n=4.
1279Y. Krishnan et al. / Biochimica et Biophysica Acta 1823 (2012) 1273–1284actively translated. For qRT-PCR the polysome gradients were divided
into four fractions (Fig. 4C underlined segments). The shape and loca-
tion of the peaks did not change signiﬁcantly between untreated and
treated conditions. A change in the ratio of peak heights would signal
a global change in translation and this would presumably affect many
cellular proteins. That the polysome proﬁle shapes are not signiﬁcant-
ly changed upon kinase stimulation is consistent with our previous
observation that cAMP-dependent increase of HERG protein was spe-
ciﬁc and did not alter other proteins we assayed [13],. The qRT-PCR
analysis showed that HERG mRNA is highest in fraction 4 (high mo-
lecular weight polysomes) in control samples which indicates that it
is highly actively translated at baseline. The resolvable distribution
of HERG mRNA showed no change with CPT-cAMP treatment
(Fig. 4D). The controls were GAPDH and actin which are both abun-
dantly expressed in HEK cells (Fig. 4E–F). Both GAPDH and actin
are highest in fraction 4 and the distribution does not change
signiﬁcantly.
We previously showed that PKC activation also increased the
abundance of HERG channel by a mechanism(s) that only partially
overlap with those for PKA [12]. To investigate his we did polysomal
proﬁling after PKC activation with PMA for 6 h (Fig. 5). The polysome
proﬁles (Fig. 5A–B) are similar in the height and shape of the peaks.
The distribution of HERG mRNA is highest in fraction 4 and this
does not change signiﬁcantly with PKC activation (Fig. 5C). Control
mRNAs for GAPDH and Actin are not changed signiﬁcantly with
PMA treatment (Fig. 5D–E). Taken together, the polysome proﬁling
data indicate that HERG mRNA is very actively translated at baseline
and that kinase activation does not enhance channel abundance by
raising the translation from low to high rates. The limitation of this
assay however, resides in the inability to resolve among the higher
density polysomes, particularly for long mRNAs such as HERG. Thus,the technique does not allow us to detect changes from high to very
high levels of translation.
3.6. Transcriptional inhibition abrogates the cAMP-mediated
HERG enhancement
Although kinase stimulation enhances HERG channel abundance
in the absence of changes in HERG mRNA we sought to determine if
new transcription of other intermediate protein co-factors were re-
quired for the effect. The fact that kinase-dependent regulation of
translation could not be reconstituted in the cell-free IVT system
suggested that such an additional co‐factor was required. Fig. 6A
shows protein abundance for HERG and various other candidate co-
factor proteins and compares cAMP treatment with transcriptional
inhibition by actinomycin-D in stably expressing HEK-HERG cells.
Cells were treated with DMSO vehicle (control), 5 μg/ml actinomycin-
D alone, or 5 μg/ml actinomycin-D together with 50 μM CPT-cAMP
added simultaneously and cells were incubated for 6, 12, or 24 h. The
cells were then lysed in NDET, and cytoplasmic lysates were assayed
for HERG by Western blot. Over a time course of 6–24 h, cAMP treat-
ment resulted in a 1.5–2.5 fold increase in HERG protein abundance
(Fig. 6B). In the presence of actinomycin-D this effect was prevented.
In light of the previous ﬁndings by Chen et al. 2009 that the HERG
mRNA remains stable and does not increase with 24 h of kinase activa-
tion, our ﬁndings suggest that a short‐lived and/or newly transcribed
protein is required for the PKA‐mediated increase in HERG protein
abundance [13]. Three obvious candidate proteins are the PKA catalytic
and regulatory subunits and the scaffolding/ signaling protein 14-3-3
which interacts with HERG in a PKA-dependent fashion [9]. We
immuno-blotted for these proteins and found no signiﬁcant change in
their abundances with the kinase stimulation, transcriptional inhibition
Fig. 5. PMA treatment does not alter HERG mRNA association with polysomes.Parts A and B show polyribosomal proﬁles for untreated and 6-hour PMA treated conditions. The y-axis
shows absorbance at 254 nmplotted against increasing gradient densitywhere heaviest componentswill sediment to the right. The underlined segments 1–4 showwhere fractionswere
collected for subsequent qRT-PCR. Parts C-E show summary data for results of qRT-PCR. The y-axis values represent percent of total RNA that is comprised by (C) HERG, (D) GAPDH, and
(E) Actin, respectively per fraction. Open bars show the untreated condition while shaded bars show the cAMP treated condition. Differences between treated and untreated conditions
were not signiﬁcant, n=4.
Fig. 6. Transcriptional inhibition abolishes the cAMP-induced increase in HERG abundance.Part A, a series of immunoblots from HEK-HERG stable cells of HERG and tubulin under
control (DMSO), CPT-cAMP treated, actinomycin-D treated, and combination cAMP and actinomycin-D treatment at three time points 6, 12, and 24 h. HERG appears as a doublet
and tubulin was used as the loading control. Lower panels show blots of PKA catalytic subunit-α, PKA regulatory subunit RIIα and multiple isoforms of 14-3-3. Part B shows quan-
tiﬁcation and summary data for the experiment. Fold change in the ratio of HERG protein over tubulin is plotted per treatment condition for each of the three time points. Control
levels are normalized to 1.0 for all time points. Differences between the control and CPT-cAMP treated conditions are signiﬁcant as indicated, n=5 and * p valueb0.05, ** p valueb0.01.
Differences between the control and act-D conditions were not statistically signiﬁcant. Differences between the control and combination treatment conditions were also not statistically
signiﬁcant. There were no signiﬁcant changes with treatments compared to control for the levels of PKAcat, PKA RIIα and 14-3-3.
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Fig. 7. 14-3-3 and KCNE protein binding do not affect the cAMP-induced increase in
HERG abundance.Part A shows immunoprecipitations (IP) from blank HEK or stably
expressing HEK-HERG cells with additional transient transfection. Transient transfec-
tions were with 14-3-3ε, 14-3-3Δη (dominant negative mutant), and difopein
(peptide blocker). The ﬁrst two lanes of the top panel show a negative control,
immunoprecipitation in HEK cells that do not express HERG. Top panel shows input
lanes and IP lanes, where HERG is enriched in the IP, and another negative control
NS which is mock immunoprecipitation with non-speciﬁc IgG. Lower panel shows
14-3-3 isoforms as two distinct bands which co-immunoprecipitated with HERG. The
dominant negative mutant 14-3-3Δη migrates at a higher molecular weight.
Transient transfection with 14-3-3Δη decreased the amount of endogenous 14-3-3
(lower band) that co-immunoprecipitated with HERG. Transient transfection with
difopein abolished the HERG and 14-3-3 binding and thus 14-3-3 is absent in that
lane. Part B shows an immunoblot of stably expressing HEK-HERG cells with various
transient transfections and 24‐hour CPT-cAMP treatment. Transient transfections are
with GFP, 14-3-3ε, 14-3-3Δη, and difopein. Upper panel shows HERG protein abun-
dance increases with CPT-cAMP treatment under all transfection conditions. The
lower panel shows tubulin as the loading control. Part C shows quantiﬁcation and sum-
mary data for the experiment in part B. The fold changes in HERG normalized to tubulin
are similar for all the transient transfection conditions. The differences between GFP
transfected and 14-3-3ε, 14-3-3Δη, or difopein transfected groups are not signiﬁcant,
n=8–27. Panel D shows immunoblots of HEK_HERG cells transiently transfected
with GFP (HERG), mink (KCNE1) or MiRP1 (KCNE2) at baseline and after 24-hour stim-
ulation with CPT-cAMP. The cAMP-dependent induction of HERG was not signiﬁcantly
altered by the co-expression of the KCNE family of interacting proteins.
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nase enhancement of HERG synthesis remains unknown.
3.7. 14-3-3 interactions do not alter the PKA‐mediated increase in HERG
abundance
One potential role for 14-3-3 is to assist in trafﬁcking of mem-
brane proteins from the ER to the plasma membrane in a
phosphorylation-dependent fashion [23]. Since 14-3-3 is known to
interact with HERG upon phosphorylation [9], we hypothesized
that 14-3-3 could be mediating the observed increase in HERG
abundance. 14-3-3 has been shown to modulate trafﬁcking and
ER exit of a few other membrane proteins such as the nicotinic ace-
tylcholine receptor (nAchR) and the KCNK3 potassium channel
[24,25]. To explore the participation of 14-3-3 in the CPT-cAMP
stimulated increase in HERG, we used two different constructs to
disrupt the interaction. The dominant-negative mutant 14-3-3Δη
R56,60A prevents 14-3-3 dimerization such that excess mutant pro-
tein will bind available sites on HERG but block dimerization of
other 14-3-3 subunits [26]. We also used difopein—a dimer of the
R18 peptide that is an effective tool to block 14-3-3 binding to
any classical targets [16]. We compared the efﬁciency of these
two methods (Fig. 7A). Difopein (difo), 14-3-3Δη R56,60A (Δη),
and additional wild-type 14-3-3ε were transiently transfected into
HEK-HERG cells. The HERG channel complex was isolated by immu-
noprecipitation using a HERG speciﬁc antibody. As shown in the
lower panel of Fig. 7A, co-immunoprecipitation of the endogenous
14-3-3 with HERG protein was increased in the presence of addi-
tional 14-3-3ε. Over-expression of 14-3-3Δη largely suppressed
endogenous 14-3-3 binding in favor of the mutant and difopein
completely blocked HERG/14-3-3 binding.
We next tested the effect of blocking the 14-3-3/HERG interaction
on the cAMP-dependent augmentation of protein abundance
(Fig. 7B–C). The Western blot shows stably expressing HEK-HERG
cells with the various co-transfections: GFP, 14-3-3ε, 14-3-3Δη,
difopein and 24-hour cAMP stimulation. The enhancement of HERG
with cAMP treatment was preserved in all conditions tested
(Fig. 8C). This suggests that the PKA-mediated increase HERG abun-
dance occurs independently of interactions with 14-3-3 proteins.
3.8. MiRP (KCNE) proteins in the cAMP/PKA augmentation of HERG
Another obvious family of HERG-interacting proteins to consider
as playing a role in the kinase-mediated augmentation of channel
translation is that encoded by the KCNE1 and KCNE2 genes—minK
and MiRP1 [15,43]. To examine the effects of KCNE subunit co-
expression on the kinase-mediated enhancement of HERG we tran-
siently co-transfected either KCNE1 (minK) or KCNE2 (MiRP1) with
HERG in HEK cells and applied 50 μM CPT-cAMP for 24 h prior to im-
munoblot analysis (Fig. 7D). Activation of cAMP/PKA increased the
abundance of HERG signal in both groups to a comparable degree as
in cells transfected with HERG alone with no statistically signiﬁcant
difference. Thus, minK and MiRP1 interaction with HERG are not me-
diators of regulators of the kinase-dependent enhancement of chan-
nel synthesis.
4. Discussion
In this work we have examined possible underlying mechanisms
that could contribute to the speciﬁc, kinase-mediated increase in
HERG protein abundance. We explored cellular aspects of PKA signal-
ing that might contribute to changes in HERG protein abundance, we
investigated changes in HERG translation rates and we examined po-
tential involvement of altered channel degradation. We showed that
the phosphomimetic HERG mutant protein increases in abundance
upon PKA or PKC stimulation, albeit to a lesser degree than wild‐type HERG. Given that the phospho-null mutant increased upon
PKA activation even less than the phosphomimetic HERG [13], we
posit that phosphorylation of HERG is necessary but not sufﬁcient to
produce the increase in protein abundance. The augmentation of the
phosphomimetic HERG-SD upon PKA stimulation strongly suggests
the presence of additional PKA targets that necessary for the channel
Fig. 8. Model of HERG translation and key mediators.A schematic representation of HERG synthesis at the ER and key mediators that regulate the process. The fully synthesized
HERG monomer is shown at right on the ER membrane with cytosolic N and C-termini and six transmembrane domains. At left is shown a simpliﬁed view of the ribosomal complex
as it translates HERG mRNA into protein. The large and small subunits join with the translocon complex to synthesize the nascent HERG peptide. PKA and increased levels of cAMP
may be responsible for mediating synthesis or turnover of an unknown co-factor. Several possibilities exist for the role of the co-factor and may play a part in aiding or accelerating
HERG synthesis.
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not able to recapitulate PKA-dependent enhancement of HERG fur-
ther points to the existence of a cellular co-factor that is not present
in the reticulocyte lysate system. Such a co-factor could be a small
molecule messenger or protein whose expression or activity is in-
duced by PKA—the latter is clearly possible since no de novo tran-
scription of proteins occurs in the reticulocyte lysate system. That
HERG translation in the cell-free system was unregulated by PKA ac-
tivity perturbation also suggests that baseline translation does not ab-
solutely require PKA activity.
Our investigations with transcriptional inhibition using actinomycin-
D produced two important ﬁndings pertaining to kinase-regulated
synthesis if HERG. First, we conﬁrmed that kinase activation did not
enhance the stability of HERG mRNA in actinomycin-D-chase experi-
ments that abolished new transcription (Fig. 5A). Second, inhibition of
new transcription prevented the kinase enhancement of HERG abun-
dance. In light of our previous ﬁnding that HERG mRNA levels remain
unperturbed by 24 h of cAMP treatment [13], our current results suggest
that 1) increased levels of HERG mRNA are not responsible for the
increase in HERG protein abundance and 2) that there is a PKA-
responsive, short-lived or newly transcribed protein co-factor that is
required for the regulatory process. These ﬁndings are consistent with
the cell-free IVT results suggesting that a cellular co-factor is necessary
for kinase-mediated augmentation of HERG channel abundance. Some
initial candidate proteins we considered were PKA catalytic and regula-
tory subunits, 14-3-3 however; kinase activation did not affect the abun-
dance of these proteins
The evidence from the present study and our prior work points to-
wards accelerated translation of the HERG message. In an attempt to
gain further insight into this process we utilized polysomal proﬁling
as a measure of rates of speciﬁc mRNA translation. These experiments
showed us that HERG is translated at a high level at baseline and that
this is not detectably accelerated by PKA or PKC activation. There are
several limitations to this analysis however, that need to be consid-
ered when interpreting. The HERG mRNA is a large message
(3480 bp for coding region alone), thus we expect it to sediment in
a relatively heavy polysome fraction even if it were sub-maximally
translated compared to smaller proteins for which this analysis has
been used. Furthermore, there is an inherent limitation of the resolu-
tion in the high molecular weight/density range using sucrose gradi-
ents that precludes the ability to distinguish quantitative differences
in this range. Thus, it is likely that HERG translation rates may in-
crease within a moderate to high range that is not resolvable by the
technique.Emerging theories support a role for regulation of translation efﬁ-
ciency as a major contributor to protein abundance [27,28]. Just how
PKA activation enhances an already actively translating HERG channel
is yet to be precisely determined. Our interpretation of the results fa-
vors the existence of a PKA-responsive protein co-factor(s) that in
combination with direct phosphorylation of the channel upregulate
synthesis of HERG. To date, the identity of such co-factors remains
elusive. One large class of proteins to consider would be chaperones.
In our previous study, we found that geldanamycin, an Hsp90 inhibi-
tor, abolished the kinase-dependent increase in HERG abundance. It is
plausible that a chaperone is speciﬁcally required for HERG synthesis
and that this chaperone/co-factor has a short life cycle (Fig. 8). It
could be rapidly transcribed in response to increased cAMP or an in-
crease in HERG synthesis and then subsequently degraded. Several
candidate chaperones such as Hsp90, Hsc/Hsp 70, FKBP38 and
Hsp40 have been identiﬁed in proteomics screens to interact with
HERG [22,29,30]. Further investigation is necessary to determine
each of the chaperones that interact with HERG and if the
chaperone-HERG interactions are regulated by increased cAMP or
PKA activation.
It is possible that speciﬁc aspects of HERG mRNA secondary struc-
ture or codon usage may affect translation and be regulated by PKA
signaling. The secondary structure of mRNA is known to affect many
aspects of translation such as recruitment of initiation factors and
the initiation process itself [31]. There are also new theories about hi-
erarchical recruitment of some mRNAs to the ER-associated ribo-
somes in order to translate proteins and how this is regulated [32].
An interesting avenue of further exploration would be to determine
the spatial distribution of ribosomes on the HERG mRNA (ribosome
density) and if this pattern could be regulated in a PKA-dependent
manner [33,34].
Another factor to consider is the folding of nascent HERG channels.
Many proteins achieve their native conformations co-translationally
and this is an important point of regulation. An interesting review
notes that the coiled-coil motif in certain proteins can be regulated
by phosphorylation and as an example a study by Szilak et al.
showed that the bZIP protein had increased stability and enhanced
functionality by PKA-mediated phosphorylation of its coiled‐coil
motif [35,36]. HERG is thought to contain a tetramerization coiled‐
coil domain in its distal C-terminus, which is in the vicinity of the
fourth PKA consensus site, and this could possibly be a site for regula-
tion [37].
Many studies have shown HERG is a protein that is prone to mis-
folding and increased degradation by the proteasome [21,38,39].
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associated degradation (ERAD) and the ubiquitin-proteasome path-
way, so we sought to determine whether proteasomal inhibition
was a point of regulation which could be responsible for the increase
in protein abundance. We found that pharmacological proteasome in-
hibition changed HERG abundance modestly but did not cause a sig-
niﬁcant fold change compared to kinase activation. We also
considered recycling of HERG and through 24-hour lysosomal phar-
macological inhibition, we determined that the changes in HERG pro-
tein abundance were minor, and could not account for the 2–4 fold
increase observed with kinase activation. HERG has been shown to
take an atypical route to the plasma membrane possibly involving an
endosomal compartment as well as regulation at the ER-Golgi interme-
diate compartment [40,41]. It is possible that a portion of HERG resides
in these alternative compartmentsmay not be amenable to the pharma-
cological inhibition techniques thatwe used. Considering that HERG has
a longhalf-life (~12 h) and that our previous data showed an increase in
protein abundance as early as 4 h with a maximal fold change of 4–5
fold at 24 h, it appears unlikely that a change in degradation could ac-
count for the majority of the increase we observe. Another degradation
pathway thatwe did not directly investigate is theupstreamsignaling of
the unfolded protein response (UPR). One study showed that heterolo-
gous over-expression of an LQT2 mutant activated the UPR pathway
[42]. It is conceivable that a baseline level of UPR response controls
wild‐type HERG protein abundance and that activation of PKA-
mediated pathway inhibits the baseline amount of degradation.
A potential limitation of our study is that the experiments were
carried out in a heterologous over-expression cell culture system
which imposes a signiﬁcantly different context than that of a car-
diomyocyte. It is possible that the cardiomyocyte contains speciﬁc
isoforms or different expression patterns of the possible key media-
tors we have discussed above. Nevertheless, we have shown that na-
tive ERG channel protein is upregulated in rabbit myocytes upon PKA
or PKC stimulation and heterologously expressed HERG in rat neona-
tal myocytes is also upregulated with PKA stimulation [12–14]. Fur-
ther investigation is warranted to understand how HERG synthesis
or trafﬁcking is truly regulated in the cardiomyocyte and how this
changes upon adrenergic stimulation.
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